Physicians' Academy for Cardiovascular Education

Anticoagulation

Unexpected findings when comparing DOAC with VKA in rheumatic AF

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

FXIa inhibition in non-cardioembolic stroke patients

3' education - Aug. 29, 2022 - Ashkan Shoamanesh, MD

Management of cancer-associated VTE

10' education - May 12, 2022 - Prof. Stavros Konstantinides, MD

Optimizing oral anticoagulation management for patients with AF

10' education - May 3, 2022 - Prof. Robert Storey, MD

A positive view on a negative trial with DOAC after TAVR

3' education - Apr. 19, 2022 - Megan Coylewright, MD

Atrial fibrillation: From risk prediction to clinical outcomes

10' education - Apr. 6, 2022 - Prof. Stefan Hohnloser, MD

Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk

3' education - Jan. 11, 2022 - Prof. Freek Verheugt, MD, PhD

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

No superiority with NOAC compared to standard care following TAVI

5' education - May 17, 2021 - Jean-Philippe Collet, MD, PhD

Clinical outcomes with low dose vs. high dose DOAC in AF

5' education - Mar. 30, 2021 - Prof. Jan Steffel, MD

No decrease in thrombotic complications in second COVID-19 wave

5' education - Feb. 4, 2021 - Fleur Kaptein, MD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI

5' education - Aug. 31, 2020 - Prof. Menno Huisman, MD

COVID-19 associated thrombotic complications

5' education - Apr. 22, 2020 - Erik Klok, MD, PhD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events

3' education - Mar. 29, 2020 - Dr. Marc P. Bonaca, MD - ACC 2020

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence

10' education - Mar. 29, 2020 - Prof. Menno Huisman - ACC 2020

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia

Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Tamar de Vries, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Direct Factor Xa inhibitor does not mitigate worsening of heart failure in HFrEF patients

3' education - Aug. 27, 2018 - Prof. Faiez Zannad, Vandoeuvre Les Nancy, France

How to manage DOAC-related bleeding

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Giving NOAC treatment at myocardial injury after non-cardiac surgery lowers major vascular complications

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - P.J. Devereaux - Hamilton, ON, Canada
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

Comparing anticoagulants for AF: Which OAC is best for patients with dementia?

Literature - Apr. 11, 2023 - Lin KJ, et al. - JAMA Netw Open. 2023

In an American comparative effectiveness study, the absolute reduction of ischemic stroke or major bleeding with apixaban versus dabigatran, rivaroxaban, or warfarin was greater in AF patients with than in those without dementia.

Antidote reverses FXa inhibitor anticoagulation after acute major bleeding

Literature - Mar. 28, 2023 - Milling TJ Jr et al. - Circulation. 2023

In the final ANNEXA-4 cohort of 479 patients with factor Xa (FXa) inhibitor–related major bleeding, andexanet alfa reduced anti-FXa activity and was associated with good or excellent hemostatic efficacy in 80% of them.

No indication for oral anticoagulation after TAVI: SAPT outperforms DAPT and DOAC-based regimens

Literature - Mar. 20, 2023 - Guedeney P, et al. - Eur Heart J Cardiovasc Pharmacother. 2023

In a network meta-analysis of 7 RCTs, single antiplatelet therapy (SAPT) reduced the bleeding risk following TAVI by 55% compared with dual APT and also direct oral anticoagulants in patients with no indication for chronic oral anticoagulation, with no increase in all-cause death.

Longer DOAC treatment reduces risk of recurrent VTE with no increased bleeding risk

Literature - Feb. 13, 2023 - Ageno W, et al. - BMJ. 2022

In patients with isolated distal deep vein thrombosis, extending rivaroxaban treatment by another 6 weeks resulted in a 41% lower risk of recurrent venous thromboembolism (VTE) compared with placebo.

Monotherapy with oral anticoagulant beyond 1 year after PCI as effective and safe as dual therapy in stable AF patients

Literature - Dec. 5, 2022 - Jensen T, et al. - Eur Heart J Cardiovasc Pharmacother. 2022

European AF guidelines recommend treating patients with stable AF and an increased risk of stroke beyond 1 year after PCI with anticoagulant monotherapy, rather than dual therapy with an oral anticoagulant and antiplatelet drug. However, the evidence for this is scarce.

DOAC vs. standard of care after TAVR: risk of valve thrombosis and clinical outcomes

Literature - Oct. 17, 2022 - Montalescot G, et al. - JACC Cardiovasc Interv. 2022

In an ATLANTIS substudy, apixaban reduced the risk of valve thrombosis after successful TAVR compared with antiplatelet therapy but not compared with VKAs. This coincided with a nonsignificant higher rate of thromboembolic and bleeding events.

Unexpected findings when comparing DOAC with VKA in rheumatic AF

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD
In a subpopulation of patients with rheumatic heart disease and AF, the effect of rivaroxaban vs. VKA was examined for the composite outcome of stroke, systemic embolism, MI and death from vascular or unknown cause.

ESC 2022 In a subpopulation of patients with rheumatic heart disease and AF, the effect of rivaroxaban vs. VKA was examined for the composite outcome of stroke, systemic embolism, MI and death from vascular or unknown cause.

Factor XIa inhibitor for secondary prevention in patients with ischemic stroke or TIA

News - Sep. 6, 2022

ESC 2022 In the phase 2 AXIOMATIC-SSP trial, five doses of the FXIa inhibitor milvexian were examined for secondary prevention in patients with previous ischemic stroke or TIA.

FXIa inhibition in non-cardioembolic stroke patients

3' education - Aug. 29, 2022 - Ashkan Shoamanesh, MD
Ashkan Shoamanesh gives a summary of the primary endpoint results and exploratory analyses of the phase 2 PACIFIC-STROKE trial with asundexian in patients with non-cardioembolic stroke.

ESC 2022 Ashkan Shoamanesh gives a summary of the primary results and exploratory analyses of the phase 2 PACIFIC-STROKE trial with asundexian in patients with non-cardioembolic stroke.

Findings from a phase 2 study with FXIa inhibitor in non-cardioembolic ischemic stroke

News - Aug. 28, 2022

ESC 2022 There was no reduction of ischemic stroke or covert infarct with the FXIa inhibitor asundexian in patients with non-cardioembolic ischemic stroke. Exploratory analyses may give some insights about where and in whom benefit of this drug may be observed though.

Phase 2 trial with novel factor XIa inhibitor after acute MI

News - Aug. 28, 2022

ESC 2022 Following an acute MI, asundexian (oral factor XIa inhibitor) in addition to DAPT was shown to be safe but did not reduce ischemic events compared with placebo in a phase 2 trial.

Standard of care with VKAs does suffice in rheumatic AF

News - Aug. 28, 2022

ESC 2022 VKAs reduced ischemic stroke and mortality in patients with rheumatic AF compared with rivaroxaban without increasing major bleeding risk, according to the first RCT on anticoagulation in this population.